Physician profile
Anna Wnuk
NPI 1740015668
$2,136.71
in general payments reported to CMS, 2019-2025
27 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $258 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $475.45 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $355.91 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $351.41 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $145.70 | 2025 | Airsupra, Breztri |
| Pfizer INC. | $83.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.42 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $67.45 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $63.24 | 2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $59.53 | 2025 | Trintellix |
| Exact Sciences Corporation | $55.22 | 2025 | The Cologuard Plus Collection Kit |
| Abiomed | $40.52 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $35.13 | 2025 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $34.64 | 2024-2025 | Zoryve |
| Ibsa Pharma INC. | $32.70 | 2024-2025 | Licart, Tirosint, Flector |
| Phathom Pharmaceuticals, INC. | $31.37 | 2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.37 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.54 | 2025 | Xifaxan |
| Biogen, INC. | $22.77 | 2024 | Leqembi |
| Globus Medical, INC. | $20.84 | 2025 | Senza |
| Amgen INC. | $18.29 | 2025 | Repatha, Otezla |
| Actelion Pharmaceuticals US, INC. | $18.26 | 2025 | Uptravi, Opsumit |
| Millicent US INC | $15.49 | 2025 | Femlyv |
| Neurocrine Biosciences, INC. | $15.40 | 2025 | |
| Lundbeck LLC | $15.22 | 2025 | Rexulti |
| Almatica Pharma LLC | $15.10 | 2025 | Loreev Xr |
| Paratek Pharmaceuticals, INC. | $14.36 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $13.70 | 2025 | Gardasil 9, Enflonsia, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Wnuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.